Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Novel immunotherapeutic approach could improve outcomes for patients with advanced bladder cancer

Noguchi explained that immunotherapy has emerged recently as a viable and attractive strategy for the treatment of advanced cancer.

18 Nov 2015

Viralytics enters into clinical trial collaboration agreement with MSD

Viralytics Limited announced today that it has entered into a clinical trial collaboration agreement through subsidiaries of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. (known as MSD outside the United States and Canada) to evaluate the combination of Viralytics' investigational cancer immunotherapy CAVATAK, with MSD's KEYTRUDA, an anti-PD-1 (programmed death receptor-1) therapy.

6 Nov 2015

Urinary biomarkers for bladder cancer diagnosis fall short of mark

Authors of a meta-analysis question the accuracy of urinary biomarkers for diagnosing the initial incidence or recurrence of bladder cancer.

4 Nov 2015

Liposomal sizing and the Coulter principle: an interview with Professor Melvin E. Klegerman

For about the last 25 years, the cardiology group here have been developing a platform technology for both the diagnosis and treatment of atherosclerosis.

From Beckman Coulter Life Sciences - Particle Counting and Characterization 28 Oct 2015

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that it will provide clinical laboratory testing using the PD-L1 IHC 22C3 PharmDx immunohistochemistry companion diagnostic.

From Quest Diagnostics 7 Oct 2015

Oxford Gene Technology launches Cytocell FISH probe for bladder cancer

Oxford Gene Technology (OGT), The Molecular Genetics Company, has launched its CE-IVD labelled Cytocell Aquarius® P16/3c/7c/17c Probe Kit, a cost-effective, ready-to-use fluorescence in situ hybridisation (FISH) probe kit for non-invasive detection of bladder cancer — for sale in Europe.

From Oxford Gene Technology 6 Oct 2015

Mycobacterium could be more effective in treating superficial bladder cancer, study finds

Universitat Autònoma de Barcelona researchers have found a mycobacterium that is more effective in treating superficial bladder cancer and does not cause infections, unlike those used up to now.

6 Oct 2015

OncoGenex meets target enrollment in apatorsen Phase 2 trial

OncoGenex Pharmaceuticals, Inc. announced today that Borealis-2, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients. Designed to evaluate apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy, Borealis-2 is sponsored by Hoosier Oncology Group and is being conducted at 27 sites across the United States.

30 Sep 2015

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

An international team of cancer researchers that included UT Southwestern Medical Center physicians announced "game-changing results" using the immunotherapy drug nivolumab to treat certain lung cancers that failed to respond to first-line therapies.

29 Sep 2015

Phase II IMvigor 210 data shows atezolizumab may prevent progression of metastatic urothelial bladder cancer

Data presented today at the 2015 European Cancer Congress (ECC) demonstrates that the investigational immunotherapy atezolizumab may prevent progression of metastatic urothelial bladder cancer (mUBC) in all age groups by 2.1 months.

29 Sep 2015

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.

23 Sep 2015

Study demonstrates effectiveness of new approach to protect humans from infectious disease

There are two common approaches to protecting humans from infectious disease: Targeting pathogens and parasites with medicines like antibiotics, or dealing with the conditions that allow transmission.

8 Sep 2015

BioLight Life Sciences Investments reports operational and financial results for Q2 2015

BioLight Life Sciences Investments, a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today reported operational and financial results for the second quarter ended June 30, 2015.

1 Sep 2015

MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

Bile duct cancer is rare and is usually detected too late. Often only extensive liver surgery can help or, in rare cases, liver transplantation. But which patients will benefit from surgery and which will not, because their risk of cancer recurrence is too high? With the oncogene MACC1 as a biomarker, physicians for the first time have a tool to decide which treatment option is best for patients with Klatskin carcinoma, one type of bile duct cancer.

1 Sep 2015

Telesta Therapeutics receives FDA BLA Filing Notification for MCNA

Telesta Therapeutics Inc. announced today that it has received its BLA Filing Notification for MCNA from the U.S. Food and Drug Administration. This formal letter communicates that the FDA has completed its initial review of Telesta's Biologics License Application (BLA) submitted on June 29, 2015 and has accepted it for filing.

29 Aug 2015

Telesta closes US$28.6 million in private placement financing

Telesta Therapeutics Inc. announced today that it has closed a private placement financing of US$28.6 million. This transaction was led by several prominent U.S. healthcare investors, including Consonance Capital Investors, Boxer Capital of Tavistock Life Sciences and Omega Funds. In addition, certain members of the senior management team and board of directors of Telesta participated in the transaction.

19 Aug 2015

Researchers develop new way to personalize treatments for aggressive bladder cancer

Researchers at UC Davis, in collaboration with colleagues at Jackson Laboratory, have developed a new way to personalize treatments for aggressive bladder cancer.

14 Aug 2015

WI Harper Group announces investment in Cold Genesys

WI Harper Group, a leading US & China, cross-border early growth and expansion stage venture capital firm, today announced an investment in Cold Genesys Inc, a clinical-stage privately-held biotech company developing oncolytic immunotherapies for cancer.

6 Aug 2015

Certain genes exposed to harsh environmental factors can increase diabetes risk

Arsenic, which can be present in ground water, modifies an enzyme that alters the secretion of insulin in the pancreas. Physicians, usually, show type II diabetes as a consequence of an exaggerated food intake and lack of exercise; however, there are about 50 genes that cause changes in the DNA, known as polymorphisms, that when combined with harsh environmental factors are at increased risk of developing the disease, mentioned PhD Marta Ostrosky Wegman, director of the Institute for Biomedical Research the National University of Mexico (UNAM).

5 Aug 2015

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands.

5 Aug 2015

Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Novel immunotherapeutic approach could improve outcomes for patients with advanced bladder cancer

Viralytics enters into clinical trial collaboration agreement with MSD

Urinary biomarkers for bladder cancer diagnosis fall short of mark

Liposomal sizing and the Coulter principle: an interview with Professor Melvin E. Klegerman

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Oxford Gene Technology launches Cytocell FISH probe for bladder cancer

Mycobacterium could be more effective in treating superficial bladder cancer, study finds

OncoGenex meets target enrollment in apatorsen Phase 2 trial

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

Phase II IMvigor 210 data shows atezolizumab may prevent progression of metastatic urothelial bladder cancer

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

Study demonstrates effectiveness of new approach to protect humans from infectious disease

BioLight Life Sciences Investments reports operational and financial results for Q2 2015

MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

Telesta Therapeutics receives FDA BLA Filing Notification for MCNA

Telesta closes US$28.6 million in private placement financing

Researchers develop new way to personalize treatments for aggressive bladder cancer

WI Harper Group announces investment in Cold Genesys

Certain genes exposed to harsh environmental factors can increase diabetes risk

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in